Todas las investigaciones
ReclutamientoFASE3INTERVENCIONISTA

A Study of JNT-517 in Participants With Phenylketonuria (PKU)

This research study is for adults (18 and over) with a condition called Phenylketonuria (PKU). We are testing a new tablet medicine, JNT-517, to see if it's safe to use, how well it helps control PKU, and how your body reacts to it. You will either receive the new medicine or a 'dummy' tablet (placebo) without knowing which one, and there's a good chance you'll get the real medicine during the first part of the study. After about six weeks, everyone continuing in the study will receive JNT-517 for many months. Taking part will involve regular check-ups, keeping a food diary, and occasionally collecting urine samples. The study could last for about 400 days in total.

De un vistazo

Estado
Reclutamiento
Fase
FASE3
Patrocinador
Otsuka Pharmaceutical Development & Commercialization, Inc.
Objetivo de inscripción
120
Inicio
20 Oct 2025
Estimación de finalización
01 Apr 2028

¿De qué trata este estudio?

This study is designed to explore a new tablet medicine called JNT-517 for people living with Phenylketonuria, often called PKU. PKU is a lifelong condition that affects how the body breaks down a substance found in food, called phenylalanine. If not managed properly, high levels of phenylalanine can lead to health problems.

The main aim of this study is to find out if JNT-517 is a safe and effective way to help manage PKU in adults. We also want to understand how your body processes this new medicine. We're especially interested in how it affects your phenylalanine levels. By carefully studying JNT-517, we hope to contribute to new ways of helping people with PKU live healthier lives.

This important stage of research, called Phase 3, means the medicine has already been tested in smaller groups and shown some promise. Now, it's being tested in a larger group of people to confirm these findings and gather more information before it could potentially become widely available.

Puntos clave

  • This study is testing a new PKU tablet, JNT-517, in adults.
  • It aims to check the medicine's safety and how well it works.
  • You might take JNT-517 or a dummy pill (placebo) at first.
  • Participation involves regular check-ups, keeping a food diary, and taking the study medicine twice daily.
  • The total study time could be around 400 days.
  • Puedes dejar de participar en cualquier momento.

¿Quién puede ser elegible?

To join this study, you need to be an adult (18 years old or over) with a formal diagnosis of PKU. Your phenylalanine levels in your blood also need to be above a certain level during the screening checks.

If you are currently taking other medicines for PKU, such as sapropterin or special amino acid supplements, you might still be able to join, but your dose must have been stable for at least 4 weeks before the study starts and stay stable throughout. If you've been on a medicine called pegvaliase, you would need to have stopped taking it at least 4 weeks before screening.

You also need to be willing and able to stick to a stable PKU diet, and be able to adjust it if needed during the study. There are also specific requirements for women who could become pregnant, including using effective birth control methods.

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. ¿Tienes 18 años o más?
  2. Do you have a diagnosis of PKU?
  3. Are your phenylalanine levels typically above a certain level?
  4. Are you able and willing to maintain a stable PKU diet?
  5. If you might become pregnant, are you willing to use two effective forms of birth control during the study?
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

If you decide to take part, you'll first have a screening period that could last up to 35 days. This is to make sure your diet is stable and your phenylalanine levels meet the study's requirements.

After screening, you'll take either JNT-517 or a placebo (dummy pill) twice a day for about 365 days. In the first six weeks, there's a 2 in 3 chance you'll receive JNT-517. After that, if you continue, you will definitely receive JNT-517, but at one of two possible doses, for an additional 46 weeks.

Throughout the study, you'll have regular check-ups, either by visiting a clinic or having a nurse come to your home. You'll also be asked to collect urine samples at home and bring them to the clinic on specific days. For 3 days before each study visit, you'll need to keep a food diary. The total time you could be involved in the study is up to 400 days.

Riesgos y beneficios potenciales

Taking part in any medical study has potential benefits and risks. The potential benefit of this study is that JNT-517 might help manage your PKU more effectively. However, it's also possible you might not experience any direct benefits, especially if you are in the placebo group initially. As with any new medicine, there could be side effects, which the study will carefully monitor. You will be told about all known possible side effects. Remember, joining this study is completely voluntary, and you are free to withdraw at any time without giving a reason, and it will not affect your usual medical care.

Locations (25)

  • University of California Los Angeles (UCLA) School of Medicine
    Código postal verificado
    Los Angeles, United States· Reclutamiento
  • University of Florida (UF) Health Shands Hospital
    Código postal verificado
    Gainesville, Estados Unidos· Reclutamiento
  • Universidad del Sur de Florida
    Código postal verificado
    Tampa, Estados Unidos· Reclutamiento
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Código postal verificado
    Chicago, Estados Unidos· Reclutamiento
  • Oregon Health and Science University
    Código postal verificado
    Portland, Estados Unidos· Reclutamiento
  • University of Pittsburgh Medical Center (UPMC) - Children's Hospital of Pittsburgh
    Código postal verificado
    Pittsburgh, Estados Unidos· Reclutamiento
  • Vanderbilt University Medical Center
    Código postal verificado
    Nashville, Estados Unidos· Reclutamiento
  • University of Texas Southwestern
    Código postal verificado
    Dallas, United States· Reclutamiento
  • University of Texas Health (UTHealth) Science Center at Houston
    Código postal verificado
    Houston, Estados Unidos· Reclutamiento
  • Utah Health - The University of Utah Hospital
    Código postal verificado
    Salt Lake City, Estados Unidos· Reclutamiento
  • Royal Adelaide Hospital
    Código postal verificado
    Adelaide, Australia· Reclutamiento
  • Royal Melbourne Hospital
    Código postal verificado
    Parkville, Australia· Reclutamiento

Preguntas comunes

What is Phenylketonuria (PKU)?

PKU is a genetic condition where your body can't properly process a substance called phenylalanine, which is found in many foods. If not managed, it can build up and cause health problems.

What is JNT-517?

JNT-517 is a new tablet medicine being tested to help control phenylalanine levels in adults with PKU.

¿Qué es un 'placebo'?

A placebo is a 'dummy' tablet that looks like the study medicine but contains no active drug. It helps researchers compare the effects of the new medicine.

Will I know if I'm taking JNT-517 or the placebo?

No, you won't know initially. This is called 'blinding' and helps ensure the study results are fair. Everyone who continues after the first six weeks will receive JNT-517.

¿Cuánto tiempo durará el estudio?

Including screening, your participation could last for up to 400 days, which is just over a year.

Cómo obtener más información

Otsuka Call Center

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

¿Interesado en participar?

Registra tu interés

Comparte tus detalles y el equipo de investigación para "A Study of JNT-517 in Participants With Phenylketonuria (PKU…" se pondrá en contacto contigo si puedes ser elegible. Siempre habla con tu médico antes de aceptar participar.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.